CINECA IRIS Institutional Research Information System

VITALE, Candida
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.806
EU - Europa 3.066
AS - Asia 1.390
AF - Africa 81
SA - Sud America 25
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 22
Totale 9.413
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.759
CN - Cina 926
IT - Italia 696
IE - Irlanda 494
SE - Svezia 393
DE - Germania 312
UA - Ucraina 266
AT - Austria 207
FR - Francia 187
FI - Finlandia 118
IN - India 89
VN - Vietnam 89
KR - Corea 77
GB - Regno Unito 71
SG - Singapore 65
PL - Polonia 63
SN - Senegal 54
DK - Danimarca 53
CA - Canada 41
HK - Hong Kong 39
NL - Olanda 36
BY - Bielorussia 34
GR - Grecia 28
JP - Giappone 28
RU - Federazione Russa 26
EU - Europa 21
BE - Belgio 20
CH - Svizzera 19
AU - Australia 17
BR - Brasile 17
ES - Italia 17
TW - Taiwan 12
UZ - Uzbekistan 12
IR - Iran 9
RO - Romania 9
TR - Turchia 7
IL - Israele 6
NZ - Nuova Zelanda 6
ZA - Sudafrica 6
EG - Egitto 5
ID - Indonesia 5
MX - Messico 5
TH - Thailandia 5
MA - Marocco 4
NG - Nigeria 4
PT - Portogallo 4
SA - Arabia Saudita 4
AM - Armenia 3
IQ - Iraq 3
MY - Malesia 3
PK - Pakistan 3
RS - Serbia 3
AR - Argentina 2
BD - Bangladesh 2
CO - Colombia 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
ET - Etiopia 2
LU - Lussemburgo 2
MU - Mauritius 2
NO - Norvegia 2
PE - Perù 2
PH - Filippine 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BG - Bulgaria 1
BW - Botswana 1
EC - Ecuador 1
HU - Ungheria 1
IM - Isola di Man 1
MK - Macedonia 1
MM - Myanmar 1
PA - Panama 1
TN - Tunisia 1
UY - Uruguay 1
Totale 9.413
Salva come PNG Salva come JPEG
Città #
Chandler 850
Beijing 583
Dublin 493
Ann Arbor 269
Ashburn 237
Fairfield 221
Houston 212
Vienna 206
Jacksonville 199
Medford 180
Nyköping 171
Torino 171
Wilmington 168
Dearborn 167
Princeton 144
Woodbridge 116
San Mateo 101
Seattle 91
Villeurbanne 80
Redwood City 72
Cambridge 69
Fremont 61
Dong Ket 58
Warsaw 48
New York 44
Florence 33
Washington 32
Nanjing 31
Chengdu 29
Hangzhou 29
Hefei 29
Turin 29
Pisa 28
Rome 26
Singapore 26
Milan 23
Boston 22
Los Angeles 22
Norwalk 22
Toronto 22
San Diego 21
Shanghai 21
Chennai 20
Seoul 20
Brussels 18
Guangzhou 18
Central District 17
Düsseldorf 16
Boardman 15
San Jose 15
Nürnberg 13
Wuhan 13
Hong Kong 12
Kunming 12
Hebei 11
Taipei 11
Upper Marlboro 11
Zhengzhou 11
Bologna 10
Munich 10
São Paulo 10
Duncan 9
Falls Church 9
Helsinki 9
Linden 9
Nanchang 9
Rotterdam 9
Guiyang 8
Hyderabad 8
Oerlikon 8
Ottawa 8
Paris 8
Piemonte 8
Provo 8
Pune 8
Shenyang 8
Xian 8
Changsha 7
Codogno 7
Mountain View 7
Philadelphia 7
Phoenix 7
Tokyo 7
Dallas 6
Jinan 6
Liverpool 6
Monza 6
Mortara 6
Palermo 6
Valdagno 6
Wayne 6
Bucharest 5
Casorzo 5
Chicago 5
Columbus 5
Erlangen 5
Jaipur 5
London 5
Silver Spring 5
Tauranga 5
Totale 5.988
Salva come PNG Salva come JPEG
Nome #
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 278
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives 276
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells 270
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. 190
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma 189
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 174
Richter Syndrome in Chronic Lymphocytic Leukemia 161
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells 153
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 132
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 130
Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia 128
Magic pills: new oral drugs to treat chronic lymphocytic leukemia 127
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA) 119
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice 119
CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences 116
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL) 112
IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS (SERPA) OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 104
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells 103
The tryptophan metabolism in the immune dysregulation of multiple myeloma 102
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance 101
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia 99
Role of PD-1/PD-L1 axis in the immune paresis of bone marrow Vγ9Vδ2 T cells in multiple myeloma 97
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib 97
THE LOCAL MICROENVIRONMENT PLAYS A DIFFERENT ROLE IN THE SURVIVAL OF TUMOR CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED AND UNMUTATED IMMUNOGLOBULIN (IG) VH GENES 96
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA 96
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target 93
Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs 93
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells 92
Idelalisib nei pazienti con leucemia linfatica cronica e linfoma follicolare: esperienza monocentrica real life 92
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 92
t(9;22) as secondary alteration in core-binding factor de novo acute myeloid leukemia 90
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells 89
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) 89
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS 88
IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals 87
Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia 87
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL) 87
SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE 85
Serological proteome analysis (SERPA) as a tool for the identification of tumor antigens capable of eliciting immune responses in chronic lymphocytic leukemia (CLL) 84
Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 84
Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis 83
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 83
Identification by serological proteome analysis (SERPA) of novel tumor associated antigens in chronic lymphocytic leukemia (CLL) 81
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia 80
Identification by serological proteome analysis (SERPA) of tumor-associated antigens eliciting antibody-responses in chronic lymphocytic leukemia 79
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PHASE I SAFETY PROFILE RESULTS OF THE ITALIAN TRIAL 79
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA 79
CD200 INCLUDED IN A 4-MARKER MODIFIED MATUTES SCORE PROVIDES OPTIMAL SENSITIVITYAND SPECIFICITY FOR THE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA 78
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. 77
Real life use of bendamustine in elderly patients with lymphoid neoplasia 77
Chronic lymphocytic leukemia therapy: new targeted therapies on the way 76
Bendamustine and alemtuzumab (BEN CAM) combination in relapsed and refractory chronic lymphocytic leukaemia (CLL): interim report of the italian trial 75
HIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target 73
Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method 72
Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study 71
Mutual interactions between tumor cells, the immune system and the microenvironment in chronic lymphocytic leukemia: biological insights and potential therapeutic implications 71
B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide 71
The CXCR4 downstream signaling pathways in chronic lymphocytic leukemia: a target to reverse microenvironment protection 70
LDH as Predictive Parameter in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12 70
Ofatumumab and lenalidomide for patients with relapsed or refractory chronic lymphocytic leukemia: Correlation between responses and immune characteristics 70
The Hypoxia-Inducible Factor-1 alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance 69
THE SURVIVAL OF TUMOR CELLS IN IGVH UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA IS HIGHLY DEPENDENT ON EXOGENOUS SIGNALS DELIVERED BY THE TUMOR MICROENVIRONMENT 68
Bendamustine and Alemtuzumab combination in relapsed and refractory chronic lymphocytic leukemia: interim report of the italian trial 68
Role of ward pharmacist in management of systemic antifungal drugs in hematology department of San Giovanni Battista Hospital, Turin, Italy. 68
PHENOTYPIC AND FUNCTIONAL FEATURES OF VGAMMA9/VDELTA2 T CELLS CORRELATE WITH THE MUTATIONAL STATUS OF THE TUMOR IMMUNOGLOBULINE AND WITH DISEASE AGGRESSIVENESS IN CHRONIC LYMPHOCYTIC LEUKEMIA 68
TARGETING THE CXCR4 DOWNSTREAM SIGNALLING PATHWAYS TO REVERSE MICROENVIRONMENT PROTECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 67
The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. 67
The association of dexamethasone + simvastatin to overcome environment-mediated chemoresistance of chronic lymphocytic leukemia (CLL) cells 66
The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells 65
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target 64
Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs 64
LDH Levels Predict Progression-Free Survival in Treatment-NaIVe Patients with Trisomy 12 Chronic Lymphocytic Leukemia 62
CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia 62
Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells 62
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THEIDENTIFICATION OF NOVEL TUMOR-ASSOCIATED ANTIGENS INCHRONIC LYMPHOCYTIC LEUKEMIA 61
TARGETING HIF-1 AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER TUMOR-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA 59
Targeting hif-1α regulatory pathways as a strategy to hamper tumor-microenvironment interactions in cll 59
IGHV UNMUTATED CLL B CELLS ARE MORE PRONE TO SPONTANEOUS APOPTOSIS AND DEPEND FROM THE ANTI-APOPTOTIC EFFECT OF ENVIRONMENTAL SIGNALS 58
Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia 58
Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells 58
Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12 58
Modulation of Phenotypic and Functional Features of Immune Cells in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib 57
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 57
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PRELIMINARY REPORT OF THE ITALIAN TRIAL 56
TARGETING HIF-1A AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER LEUKEMIA-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA 56
Treatment of chronic lymphocytic leukemia in the new drugs era: the state of art in the Italian landscape 56
REGULATION OF HIF-1 IN TP53 DISRUPTED CLL CELLS AND ITS INHIBITION AS A STRATEGY TO OVERCOME FLUDARABINE RESISTANCE 56
Cd200 baseline serum levels predict prognosis of chronic lymphocytic leukemia 54
Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia 53
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia 53
The role of clinical team pharmacist of San Giovanni Battista Hospital in a retrospective study invasive fungine infections: management and appropiateness. 52
Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia 49
Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia 49
Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia 48
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 46
Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia 46
Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside 44
Changes in lymphocyte subsets, angiogenic factors and plasma cytokines in patients with chronic lymphocytic leukemia during treatment with Ofatumumab and Lenalidomide 44
CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results 44
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target 44
Totale 8.711
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.887
article - articoli 0
book - libri 0
conference - conferenze 15.648
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.535
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019237 0 0 0 0 0 0 0 0 0 0 141 96
2019/20201.344 43 39 47 178 80 185 154 111 109 143 132 123
2020/20211.721 146 122 75 150 235 95 99 132 137 81 226 223
2021/20221.863 81 44 84 163 108 42 237 133 49 197 417 308
2022/20232.278 247 219 66 235 185 571 171 147 227 62 94 54
2023/2024795 114 183 61 43 50 171 23 71 7 55 17 0
Totale 9.791